Structure Therapeutics, Inc. (GPCR)
17.36
-0.81
(-4.46%)
USD |
NASDAQ |
Nov 18, 16:00
17.55
+0.19
(+1.09%)
After-Hours: 07:30
Structure Therapeutics Enterprise Value : 5.739M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 5.739M |
| November 17, 2026 | 63.54M |
| November 16, 2026 | 92.09M |
| November 13, 2026 | 194.14M |
| November 12, 2026 | 182.72M |
| November 11, 2026 | 261.93M |
| November 10, 2026 | 317.59M |
| November 09, 2026 | 294.76M |
| November 06, 2026 | 219.11M |
| November 05, 2026 | 128.48M |
| November 04, 2026 | 219.83M |
| November 03, 2026 | 219.11M |
| November 02, 2026 | 227.68M |
| October 30, 2026 | 327.58M |
| October 29, 2026 | 332.58M |
| October 28, 2026 | 299.75M |
| October 27, 2026 | 304.75M |
| October 26, 2026 | 272.64M |
| October 23, 2026 | 279.06M |
| October 22, 2026 | 331.87M |
| October 21, 2026 | 337.58M |
| October 20, 2026 | 399.66M |
| October 19, 2026 | 337.58M |
| October 16, 2026 | 271.21M |
| October 15, 2026 | 350.42M |
| Date | Value |
|---|---|
| October 14, 2026 | 328.30M |
| October 13, 2026 | 358.98M |
| October 12, 2026 | 473.16M |
| October 09, 2026 | 589.49M |
| October 08, 2026 | 598.76M |
| October 07, 2026 | 670.84M |
| October 06, 2026 | 727.22M |
| October 05, 2026 | 735.78M |
| October 02, 2026 | 741.49M |
| October 01, 2026 | 834.97M |
| September 30, 2026 | 998.39M |
| September 29, 2026 | 991.65M |
| September 28, 2026 | 1.161B |
| September 25, 2026 | 1.222B |
| September 24, 2026 | 1.229B |
| September 23, 2026 | 1.224B |
| September 22, 2026 | 1.292B |
| September 21, 2026 | 1.285B |
| September 18, 2026 | 1.156B |
| September 17, 2026 | 1.163B |
| September 16, 2026 | 1.192B |
| September 15, 2026 | 1.437B |
| September 14, 2026 | 1.401B |
| September 11, 2026 | 1.417B |
| September 10, 2026 | 1.480B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.346T |
| Novo Nordisk A/S | 145.32B |
| Merck & Co., Inc. | 383.95B |
| Prestige Consumer Healthcare, Inc. | 4.480B |
| Pfizer Inc. | 208.64B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -145.14M |
| Total Expenses (Quarterly) | 145.14M |
| EPS Diluted (Quarterly) | -1.992 |
| Earnings Yield | -22.74% |
| Normalized Earnings Yield | -23.44 |